Poor Work Efficiency is Associated with Poor Exercise Capacity and Health-Related Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

This article was published in the following Dove Press journal:
International Journal of Chronic Obstructive Pulmonary Disease

Shih-Hsing Yang¹
Mei-Chen Yang^{1,2,3}
Yao-Kuang Wu^{1,2,3}
Chih-Wei Wu^{2,3}
Po-Chun Hsieh^{1,4}
Chan-Yen Kuo^{1,5}
I-Shiang Tzeng^{1,5}
Chou-Chin Lan^{1,2,3}

¹Department of Respiratory Therapy, Fu Jen Catholic University, New Taipei City, Taiwan; ²Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; ³School of Medicine, Tzu-Chi University, Hualien, Taiwan; ⁴Department of Chinese Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation; School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan; ⁵Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan

Introduction: Chronic obstructive pulmonary disease (COPD) is a progressive disease with deteriorating cardiopulmonary function that decreases the health-related quality of life (HRQL) and exercise capacity. Patients with COPD often have cardiovascular and muscular problems that hinder oxygen uptake by peripheral tissues, resulting in poor oxygen consumption efficiency. It is important to develop new physiological parameters to evaluate oxygen consumption efficiency during activities and to evaluate its association with exercise capacity and HRQL. Work efficiency (WE) measures oxygen consumption efficiency during exercise. We hypothesize that patients with poor WE should have exercise intolerance and poor HRQL. Therefore, we aimed to evaluate the association between WE and exercise capacity, HRQL and other cardiopulmonary parameters.

Patients and Methods: Seventy-eight patients with COPD were evaluated with spirometry, cardiopulmonary exercise testing, and assessment of dyspnea score and HRQL (using the St. George's Respiratory Questionnaire [SGRQ]). Cardiopulmonary exercise testing was performed using a cycle ergometer with an incremental protocol and exhaled breath analysis to assess oxygen consumption. WE was defined as the relationship between oxygen consumption and workload.

Results: There were 31 patients with normal WE (group I) and 47 patients (group II) with poor WE. Patients with poor WE had lower exercise capacity (maximal oxygen consumption, group I vs II as 1050±53 vs 845 ±34 mL/min, p=0.0011), poorer HRQL (SGRQ score 41.1±3.0 vs 55±2.2, p=0.0002), higher exertional dyspnea score (5.1±0.2 vs 6.1±0.2, p= 0.0034) and early anaerobic metabolism during exercise (anaerobic threshold, 672±27 vs 583 ±18 mL/min, p=0.0052).

Conclusion: WE is associated with exercise capacity and HRQL. Here, patients with poor WE also had exercise intolerance, poorer HRQL, and more exertional dyspnea.

Keywords: chronic obstructive pulmonary disease, exercise physiology, work efficiency

Introduction

Chronic obstructive pulmonary disease (COPD) is an inexorable progressive disease with worsening cardiopulmonary function that decreases the endurance to perform activities of daily living.^{1,2} According to the World Health Organization (WHO), 64 million people have COPD and 3 million people have died of COPD worldwide.³ In addition, the WHO has predicted that COPD will become the third leading cause of death by 2030.³ In a recent study, patients with COPD are at a higher risk of cardiovascular mortality.⁴ COPD is characterized by dyspnea, poor health-

Correspondence: Chou-Chin Lan
Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 289, Jianguo Road, Xindian City, New Taipei City, 23142, Taiwan
Tel +886-2-6628-9779 Ext. 2259
Fax +886-2-6628-9009
Email bluescopy@yahoo.com.tw

related quality of life (HRQL), and insufficient cardiorespiratory endurance during exercise.⁵ Even in patients with mild COPD, exercise performance is compromised, and exercise intolerance is also common.⁵ Impaired exercise capacity and insufficient cardiorespiratory endurance are correlated with poor prognosis in patients with COPD.⁵ Early recognition of patients with poor cardiorespiratory endurance may help physicians to provide early management to prevent cardiovascular complications.

Traditionally, spirometry is recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for the diagnosis of COPD.^{6,7} However, the parameters of spirometry, such as forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) is a poor predictor of functional performance, cardiorespiratory endurance, and HRQL in patients with COPD.^{5,8} Although, the 6 minutes walking test or HRQL questionnaires are good tools to evaluate functional performance of patients, these parameters cannot reflect the physiological response to exercise and we cannot define the causes of poor functional performance by the 6 minutes walking distance or HRQL scores. Therefore, it is necessary to develop new parameters to evaluate exercise performance and cardiorespiratory response in patients with COPD. The cardiopulmonary exercise test (CPET) is a good tool for evaluating exercise capacity, respiratory function, and circulatory function.⁹ The physiological data from CPET can help physicians better understand the patient's cardiorespiratory responses to exercise.¹⁰

Work efficiency (WE) measures the relationship between changes in oxygen consumption (VO_2) to workload (WR).⁹ WE measures oxygen kinetics and is an index of overall oxygen consumption efficiency during exercise. However, studies about the role of WE in patients with COPD are quite limited. Since WE is an index of overall oxygen consumption efficiency, we hypothesized that patients with poor WE should have poor exercise capacity and HRQL. Therefore, this study aimed to comprehensively evaluate the relationship between WE and exercise capacity, HRQL, respiratory, and circulatory parameters in patients with COPD.

Patients and Methods

Patient Recruitment

There were 78 patients with COPD with exertional dyspnea (modified Medical Research Council, mMRC ≥ 2) who were recruited from the outpatient clinic of the

Pulmonology Department from August 2018 until June 2020.¹¹ According to WE obtained from CPET, patients were divided into two groups: group I had normal WE, and group II had poor WE.

The inclusion criteria were as follows: (1) COPD diagnosed based on the GOLD criteria with $\text{FEV1/FVC} < 70\%$; (2) patients were stable without acute exacerbations in the last 3 months, and (3) patients could move independently and were willing to perform the exercise test. We excluded (1) patients receiving pulmonary rehabilitation in the past year; (2) patients who suffered from acute exacerbation in the last 3 months; (3) patients with severe musculoskeletal diseases that rendered them unable to perform exercise tests; (4) patients with a history of other lung diseases, such as asthma, lung cancer, pneumoconiosis, bronchiectasis, tuberculosis, and interstitial lung disease; (5) patients with a history of cardiovascular diseases such as congestive heart failure, myocardial infarction, primary pulmonary hypertension, pulmonary embolism, and (6) patients who were unwilling to participate exercise tests. The study flow chart is shown in Figure 1.

The study was approved by the Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Institutional Review Board (Protocol Number: 08-XD-035) in accordance with the Declaration of Helsinki. All patients signed informed consent forms.

Pulmonary Function Test

Patients performed pulmonary function tests using a spirometer (Medical Graphics Corporation; St Paul, MN, USA), in accordance with the standards of the American Thoracic Society.¹² Patients were requested to take a maximal inspiration and then to forcefully expel air as much as possible. The grade of airflow obstruction was assessed using FEV1% according to the GOLD guidelines.¹¹

Cardiopulmonary Exercise Test

All patients underwent the CPET with an incremental, symptom-limited protocol using a cycle ergometer (Lode Corival, the Netherlands). The expired air was analyzed breath by breath (Breeze suite 6.1, Medical Graphics Corporation; St Paul, MN, USA) to evaluate oxygen consumption (VO_2), carbon dioxide output (VCO_2), tidal volume (V_T), and end tidal PCO_2 (PETCO_2). Oxygen saturation was measured using a pulse oximeter (SpO_2). The respiratory rate (RR), electrocardiogram, heart rate (HR), and blood pressure (BP) were continuously monitored.

Figure 1 Study flow chart.

The patients underwent incremental CPET with an individualized ramp protocol, and the load was set up to finish between the 10th and 12th minutes of exertion.¹³ Patients underwent a 2-minute warm-up phase (unloaded cycling), following which the WR was increased constantly in increments of 10, 15, or 20 watt/min, depending on the patient's estimated subjective functional capacity.¹³ During the exercise test, patients were requested to maintain a cycling frequency of approximately 60 revolutions per minute. Patients were requested to perform maximal exercise to evaluate their highest possible performance. The maximum effort was attained when patients showed signs of intense exertion such as sweating, unsteady biking, severe dyspnea, muscle fatigue (reluctance to continue exercising despite strong encouragement), a heart rate (HR) of >180 beats/min, or respiratory exchange rate (RER) >1.09 during exercise.¹³ The maximum VO_2 ($\text{VO}_{2\text{max}}$) was calculated by the mean values of VO_2 over the last 30 seconds of the exercise test.

WE, the relationship between VO_2 and WR during exercise,¹³ was defined as the VO_2/WR slope during exercise. The slope of the VO_2/WR relationship was

determined using linear regression analysis. The normal range for WE is 8.6–10.1 mL/min/watt. A WE of <8.6 mL/min/watt is indicative of poor WE.⁹ The VO_2 at anaerobic threshold (AT) was identified by the VCO_2 versus VO_2 plot.¹⁴ An AT of <40% of the predicted $\text{VO}_{2\text{max}}$ is indicative of low AT%.⁹ The oxygen pulse was defined as VO_2 divided by HR ($\text{O}_2\text{P} = \text{VO}_2/\text{HR}$) at maximal exercise. A O_2P of <80% of the predicted value is indicative of low $\text{O}_2\text{P}\%$.⁹

Respiratory Muscle Strength

The respiratory muscle strength, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) were measured using a pressure gauge (Respiratory Pressure Meter, Micro Medical Corp, England). MIP and MEP were measured five times, and the highest value was used as the final value.¹⁵ For the MIP, patients were asked to exhale to the residual volume and then perform a rapid maximal inspiratory effort, sustained for 1–2 seconds. For MEP, patients were asked to inspire to the total lung capacity and then perform a rapid and maximal expiratory effort, sustained for 1–2 seconds.

HRQL

HRQL was assessed using a respiratory disease-specific questionnaire. The validated Chinese version of the St. George's Respiratory Questionnaire (SGRQ), which had four components (total, symptom, activity, and impact), was used.¹⁶ SGRQ scores ranged from 100 (worst) to 0 (best).¹⁶

Dyspnea Score

The dyspnea score was evaluated using a Borg scale with 10-point scores; higher scores indicated more dyspnea.¹⁷ During CPET, dyspnea scores were evaluated at rest and during exercise.

Statistical Analysis

All parameters are expressed as mean $\pm$ standard deviation (SD). An independent sample *t*-test was used to compare parameters between the two groups. We used the Chi-square test to compare sex, stages of COPD, and smoking status between group I and group II. Correlation analyses were performed to evaluate the correlation between WE, predicted FEV1%, predicted FVC%, VO₂max, WR, O₂P %, AT%, dyspnea score, and HRQL. The strength of the correlation was determined according to Evan's classification.¹⁸ All statistical analyses were performed using SPSS, version 24.0 (SPSS, Inc., Chicago, IL, USA).

Results

Baseline Characteristics

Of the 78 patients with COPD, 31 patients had normal WE (group I) and 47 had poor WE (group II). The clinical characteristics of the patients are shown in Table 1. The mean age was 67.6 ± 9.9 years and $71.5.9 \pm 7.9$ years in groups I and II, respectively ($p > 0.05$). The mean body mass index was 23.1 ± 3.2 and 22.6 ± 4.0 kg/m² in groups I and II, respectively ($p > 0.05$). The mean FEV1% was $49.4 \pm 14.2\%$ and $47.8 \pm 17.4\%$ in groups I and II, respectively ($p > 0.05$). Ninety-four percent of patients in group I and 96% of patients in group II had moderate to very severe airflow obstruction (GOLD stages II to IV), and the severity of COPD was not significantly different between the two groups ($p > 0.05$). However, Group II had more current smokers and ex-smokers than group I ($p < 0.05$).

Respiratory Parameters of Patients with Normal and Poor WE (Figure 2)

There was no significant difference in the respiratory parameters such as FEV1/FVC% (Figure 2A), FEV1% (Figure 2B), FVC% (Figure 2C), MIP (Figure 2D), and

MEP (Figure 2E) between groups I and II ($p > 0.05$). The RR at rest (Figure 2F) was not significantly different between groups I and II ($p > 0.05$) but the RR (Figure 2G) during exercise was higher in group II than in group I ($p < 0.05$). The V_T at rest (Figure 2H) or during exercise (Figure 2I) was not significantly different between groups I and II ($p > 0.05$).

Circulatory Parameters of Patients with Normal and Poor WE (Figure 3)

WE (Figure 3A), VO₂max (Figure 3B) or AT% (Figure 3C), and O₂P% (Figure 3D) were higher in group I than in group II ($p < 0.05$). There was no significant difference between HR at rest (Figure 3E) or during exercise (Figure 3F) and MBP at rest (Figure 3G) or during exercise (Figure 3H) between the two groups ($p > 0.05$).

Gas Exchanges of Patients with Normal and Poor WE (Figure 4)

There was no significant difference between SpO₂ at rest (Figure 4A) or during exercise (Figure 4B) and PETCO₂ at rest (Figure 4C) or during exercise (Figure 4D) between the two groups ($p > 0.05$).

Exercise Capacity of Patients with Normal and Poor WE (Figure 5)

VO₂max% (Figure 5A) and VO₂max (Figure 5B) were significantly higher in group I than in group II ($p < 0.05$). However, there was no significant difference in maximal WR% (Figure 5C) and maximal WR (Figure 5D) between the two groups ($p > 0.05$).

Dyspnea Score and HRQL (Figure 6)

Dyspnea scores at rest (Figure 6A) were similar between the two groups ($p > 0.05$), but dyspnea scores during maximal exercise (Figure 6B) were significantly higher in group II than in group I ($p < 0.05$). SGRQ-total (Figure 6C), -activity (Figure 6D), -impact (Figure 6E), and -symptom (Figure 6F) scores were significantly higher in group II than in group I ($p < 0.05$).

Correlation Between WE and Lung Function, Exercise Capacity, VO₂ at the AT, O₂P, Dyspnea Score, and HRQL (Figure 7)

Comparison of important parameters such as lung function, exercise capacity, AT, HRQL and correlations between WE and these parameters are shown in Table 2. The patients of

Table I Baseline Characteristics

	All (n = 78)	Group I (n = 31)	Group II (n = 47)	p-value
Age (years)	69.9 ± 8.9	67.6 ± 9.9	71.5.9 ± 7.9	0.054
BH (cm)	162.5 ± 7.4	161.8 ± 8.1	163.1 ± 7.0	0.452
BW (kg)	60.5 ± 11.6	60.8 ± 11.3	60.4 ± 12.0	0.878
BMI (kg/m ²)	22.8 ± 3.7	23.1 ± 3.2	22.6 ± 4.0	0.559
FEV1/FVC (%)	47.5 ± 10.9	49.6 ± 11.0	46.1 ± 10.7	0.172
FEV1 (%)	48.4 ± 16.1	49.4 ± 14.2	47.8 ± 17.4	0.678
FVC (%)	80.3 ± 18.9	79.7 ± 18.1	80.7 ± 19.6	0.824
COPD stages				0.381
I	2	0	2	
II	31	15	16	
III	37	14	23	
IV	8	2	6	
Smoking				0.002*
Non-smoking	10	7	3	
Current smoking	33	6	27	
Ex-smoking	35	18	17	

Note: *p < 0.05 statistical significance as comparison between group I and II.

Abbreviations: BH, body height; BW, body weight; BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.

poor WE had lower exercise capacity, earlier anaerobic threshold, poorer HRQL and more exertional dyspnea during exercise (all p<0.05). There was no significant correlation between WE and either FEV1% (Figure 7A, p> 0.05, no correlation) or FVC% (Figure 7B, p > 0.05, no correlation). A significant correlation was found between WE and VO₂max (r = 0.4199, p = 0.0001, moderate correlation, Figure 7C), but not between WE and WRmax (p > 0.05, no correlation, Figure 7D). There were significant correlations between WE and O₂P (r = 0.3462, p = 0.0019, weak correlation, Figure 7E), VO₂ at the AT (r = 0.2818, p = 0.0124, weak correlation, Figure 7F), dyspnea score at exercise (r = 0.3918, p = 0.0004, weak correlation, Figure 7G), and SGRQ-total score (r = 0.2722, p = 0.0159, weak correlation, Figure 7H).

Discussion

There are some important findings in this study. Compared to patients with normal WE, those with poor WE had worsening HRQL, exercise intolerance, exertional dyspnea, and poor circulatory parameters. Correlation analysis revealed that WE was correlated with exercise capacity, dyspnea and HRQL. In addition, patients who were current smokers or ex-smokers had poor WE.

In patients, the efficiency of exercise depends on their respiratory (gas exchange), circulatory (oxygen delivery), musculoskeletal systems (extract oxygen to perform exercise), and metabolism by cellular mitochondria.¹⁹ WE is a measurement from VO₂ kinetics during exercise and is an index of overall oxygen consumption efficiency. The VO₂ kinetics, the rate of oxygen consumption related to work rate, is considered as an indicator of cardiovascular efficiency and coupling O₂ delivery to peripheral muscles. Uncoupling of this procedure results in the impaired ability to increase oxygen consumption. Lower WE therefore implies a poor exercise efficiency.²⁰

When the circulatory system and oxygen extraction match the demands of skeletal muscles during exercise, overall oxygen consumption efficiency is maintained. The increase in oxygen consumption is proportional to the incremental work during exercise.¹³ Normally, the VO₂/WR linearity corresponds to the increased watt, regardless of age and sex.^{13,20} However, when either oxygen delivery or oxygen extraction is impaired, the overall oxygen consumption during exercise is impaired, with presentation of a flattening or shallow downward shifting of VO₂ at a given WR and WE is decreased.^{19,20} WE, therefore, reflects the capacity of

Figure 2 Respiratory parameters. There was no significant difference in respiratory parameters such as FEV1/FVC% (A), FEV1% (B), FVC% (C), MIP (D), MEP (E), RR at rest (F), and V_T at rest (H) or during exercise (I) between group I and group II ($p > 0.05$). However, the RR during exercise (G) was higher in group II than in group I ($p < 0.05$). * $p < 0.05$ as comparison between groups I and II.

Abbreviations: MIP, maximal inspiratory pressure; MEP, maximal expiratory pressure; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; RR, respiratory rate; V_T , tidal volume.

aerobic metabolism during exercise.²⁰ The loss of the linear relationship between VO_2 and WR indicates impaired oxygen consumption efficiency. Therefore, WE that indicates VO_2 kinetics can help us assess oxygen consumption efficiency in patients with COPD.²⁰ WE can help physicians to assess the efficiency of cardiovascular oxygen delivery, and peripheral oxygen extraction.

When the metabolic demands begin to exceed oxygen delivery to the contracting muscles, anaerobic metabolism begins.²¹ During an exercise test, the AT is the exercise level that reflects the metabolic condition of anaerobic glycolysis.^{20,21} Anaerobic glycolysis results in the production of lactic acid and metabolic acidosis-stimulating chemoreceptors, which lead to excessive ventilator responses.^{20,21} When

Figure 3 Circulatory parameters. WE (A), VO_2 at maximal exercise (B) or AT (C), and O_2P (D) were higher in group I than in group II ($p < 0.05$). There was no significant difference in HR at rest (E) or during exercise (F) and in MBP at rest (G) or during exercise (H) between the two groups ($p > 0.05$). * $p < 0.05$ as comparison between group I and II. **Abbreviations:** AT, anaerobic threshold; O_2P , oxygen pulse; MBP, mean blood pressure; HR, heart rate; WE, work efficiency; VO_2 , oxygen uptake.

Figure 4 Gas exchanges. There was no difference in SpO_2 at rest (A) or exercise (B) and PETCO_2 at rest (C) or exercise (D) were between the two groups ($p > 0.05$). **Abbreviations:** SpO_2 , blood oxygen saturation by pulse oximeter; PETCO_2 , end tidal carbon dioxide.

exercise exceeds the AT, patients have high RR and minute ventilation. If the patient's oxygen consumption efficiency is poor, early anaerobic metabolism occurs during exercise. In such patients, early anaerobic metabolism results in early lactic acidosis, which in turn leads to higher RR and ventilation during exercise. Higher RR and ventilation during exercise

further results in more exertional dyspnea and exercise intolerance.²¹ In our study, we found that patients with poor WE experienced earlier AT, higher RR, and more exertional dyspnea during exercise than patients with normal WE. Exertional dyspnea and exercise intolerance are associated with poor HRQL.²² Our results further revealed that patients

Figure 5 Exercise capacity. Maximal $\text{VO}_2\%$ (A) and maximal VO_2 (B) were higher in group I than in group II ($p < 0.05$). However, there was no significant difference in the maximal workload% (C) and maximal workload (D) between the two groups ($p > 0.05$). * $p < 0.05$ as comparison between group I and II.

Abbreviation: VO_2 , oxygen uptake.

Figure 6 Dyspnea score and health-related quality of life. Dyspnea scores at rest (A) were similar between the two groups ($p > 0.05$), but dyspnea scores at maximal exercise (B) were significantly higher in group II than that in group I ($p < 0.05$). The SGRQ-total (C), -activity (D), -impact (E), and -symptom (F) scores were significantly poorer in group II than that in group I ($p < 0.05$). * $p < 0.05$ as comparison between group I and II.

Abbreviation: SGRQ, St. George's Respiratory Questionnaire.

with poor WE had poorer HRQL, including SGRQ-symptom and SGRQ-activity scores.

Oxygen delivery is a major determinant of oxygen consumption efficiency. Oxygen delivery depends on a transport system, the cardiovascular system.²⁰

Inadequate oxygen delivery to the skeletal muscles leads to poor VO_2 kinetics and anaerobic metabolism. Lower WE and early anaerobic metabolism occur in such conditions. Therefore, patients with cardiovascular dysfunction exhibit an attenuation of O_2 transport and poor WE.²⁰

Figure 7 Correlation between WE and lung function, VO_2 at maximal exercise and AT, O_2P , dyspnea score, and HRQL. There was no significant correlation between WE and FEV1% (A) or FVC% (B) (both $p > 0.05$) between the two groups. A significant correlation was found between WE and VO_2 ($r = 0.4199$, $p = 0.001$) (C), but not between WE and workload at maximal exercise ($p > 0.05$) (D). There were significant correlations between WE and O_2P ($r = 0.3462$, $p = 0.0019$) (E), VO_2 at the AT ($r = 0.2818$, $p = 0.0124$) (F), dyspnea score during exercise ($r = 0.3918$, $p = 0.0004$) (G), and SGRQ-total score ($r = 0.2722$, $p = 0.0159$) (H).

Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; VO_2 , oxygen uptake; O_2P , oxygen pulse; AT, anaerobic threshold; SGRQ, St. George's Respiratory Questionnaire; WE, work efficiency.

When oxygen delivery is impaired, VO_2 fails to linearly increase with the increase in work rate, which in turn decreases WE.²⁰ O_2P is often used as indicator of stroke volume.¹⁴ In our study, WE was significantly correlated with O_2P at maximal exercise.

Mitochondrial function is important for providing oxidative capacity in skeletal muscle during exercise.^{23,24} Therefore, mitochondrial function is critical for exercise efficiency.^{23,24} Many studies have shown that patients with COPD may have mitochondrial dysfunction, including a reduction in oxidative capacity, and enhanced reactive oxygen species (ROS) production.²³ Therefore, COPD is associated with chronic inflammation and oxidative stress.²³ It is important to assess mitochondrial function in COPD; however, muscle biopsies are needed for the determination of mitochondrial density, which is not always possible in the clinical setting. Patients with poor mitochondrial function with impaired oxidative capacity often present with poor WE.²⁴ Therefore, WE could be an indirect indicator of mitochondrial function. However, not all COPD patients suffer from mitochondrial dysfunction. The WE parameter obtained from CPET can help physicians identify patients who may have poor mitochondrial function.

Traditionally, WE is considered as a parameter of cardiovascular function that WE was considered to be reduced in cardiovascular disorders and normal in pulmonary diseases such as COPD.²⁵ However, in our

study, we found a large number (47/78) of patients with COPD had poor WE. Mirdamadi et al also evaluated 37 patients with COPD by CPET and they also found that some patients with COPD had poor WE.²⁶ They showed a significant negative correlation between WE and the body-mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index, which is one parameter of COPD severity. Patients with more severe COPD had lower WE.²⁶ Another study assessing 58 patients attending CPET showed that WE was considered as one parameter of impaired peripheral oxygenation (IPO). COPD patients with IPO pattern showed poorer circulatory parameters and more dyspnea than those without IPO.²⁷

In our study, although there were significant correlations between WE and exercise capacity, exertional dyspnea score and HRQL, the correlation strength was only weak to moderate. The causes of exercise intolerance and poor HRQL in COPD are often multiple factors including impaired ventilatory efficiency, respiratory muscle dysfunction, peripheral skeletal muscle deconditioning, cardiovascular disorders, and anxiety.²⁸ As a result, it is rational that the correlation between WE and exercise capacity is weak to moderate. Therefore, when treating COPD patients with exercise intolerance and poor HRQL, these multiple factors should be taken into consideration and appropriate treatment must be provided. In this study, we further observed that poor

Table 2 Difference and Correlation Between WE and Variables

Variables	Group I	Group II	p-value
FEV1 (%)	49.4 ± 14.2	47.8 ± 17.4	0.6777
FVC (%)	79.7 ± 18.1	80.7 ± 19.6	0.8239
VO ₂ max (mL/min)	1050±53	845 ±34	0.0011
Workload (watt)	69.6 ± 29.7	60.2 ± 23.7	0.1278
O ₂ P (mL/beats)	8.2 ± 2.1	7.0 ± 1.9	0.0088
VO ₂ at AT (mL/min)	672±27	583 ±18	0.0052
Dyspnea score at exercise	5.1±0.2	6.1±0.2	0.0034
SGRQ-total	41.1±3.0	55±2.2	0.0002
Variables	Pearson correlation (r)	p-value (two-tailed)	Strength of correlation
FEV1 (%)	0.0299	0.7947	Not significant
FVC (%)	−0.0678	0.5552	Not significant
VO ₂ max (mL/min)	0.4199	0.0001*	Moderate
Workload (watt)	0.1495	0.1914	Not significant
O ₂ P (mL/beats)	0.3462	0.0019*	Weak
VO ₂ at AT (mL/min)	0.2818	0.0124*	Weak
Dyspnea score at exercise	−0.3918	0.0004*	Weak
SGRQ-total	−0.2722	0.0159*	Weak

Note: *p < 0.05 as statistical significance.

Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; VO₂max, oxygen consumption at maximal exercise; O₂P, oxygen pulse; AT, anaerobic threshold; SGRQ, St. George's Respiratory Questionnaire.

efficiency of oxygen consumption is yet another factor associated with exercise intolerance and poor HRQL.

Clinical Implication

Exertional dyspnea, exercise intolerance, and physical inactivity are common in COPD and are strong predictors of reduced survival.²¹ Aerobic fitness during exercise is important for patients with COPD. Overall oxygen consumption efficiency during exercise depends on oxygen delivery (cardiovascular system), oxygen extraction (skeletal muscle), and mitochondrial function.¹³ Lower exercise efficiency causes patients to expend more energy for a given physical exertion and, therefore, hampers activities of daily living.²⁴ Clinically, echocardiography is often used to assess cardiac function. However, echocardiography at rest cannot assess the cardiovascular response during exercise. Mitochondrial function is important in COPD, but it is difficult to assess mitochondrial function clinically. CPET is a noninvasive exercise test that can objectively assess overall oxygen consumption efficiency by WE.¹⁹ WE provides information about the circulatory function, tissue oxygen extraction and consumption during exercise.

Limitations of This Study

This study has some limitations. First, we suggested that WE plays a role in patients with COPD. Patients with poor WE had poor exercise capacity, HRQL and more

exertional dyspnea. However, the prognostic value of WE for survival or acute exacerbation is unknown. Further studies are necessary to assess its prognostic value. Second, WE is a physiological parameter to assess overall oxygen consumption efficiency. It cannot specifically determine whether poor oxygen consumption efficiency is due to cardiovascular, muscular, or mitochondrial dysfunction. However, it is a good parameter to assess the overall oxygen consumption efficiency during exercise.¹³ This is important to understanding exercise physiology in COPD. Third, there was no control group in the current study. WE is a parameter to assess the efficiency of oxygen consumption and is not influenced by age, sex or training status. We focused on the roles of WE in patients with COPD. We aimed to compare the exercise capacity, HRQL and other parameters in patients with COPD with normal or poor WE. We did not aim to compare WE between COPD patients and normal subjects. Therefore, there was no control group in this study.

Conclusions

WE is an index of overall efficiency of oxygen consumption during exercise and is associated with exercise capacity, exertional dyspnea, and HRQL. Patients with poor WE had exercise intolerance, poorer HRQL, higher

respiratory rates, more exertional dyspnea and earlier anaerobic metabolism during exercise.

Acknowledgments

This study was supported by grants from the Taipei Tzu Chi Hospital and the Buddhist Tzu Chi Medical Foundation (TCRD-TPE-109-60 and TCMF-CP 109-02).

Disclosure

The authors have no financial or other potential conflicts of interest to disclose.

References

- Ko FWS, Sin DD. Twenty-five years of respirology: advances in COPD. *Respirology*. 2020;25(1):17–19. doi:10.1111/resp.13734
- Montagnani A, Mathieu G, Pomeroy F, et al. Hospitalization and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD): an Italian population-based study. *Eur Rev Med Pharmacol Sci*. 2020;24(12):6899–6907. doi:10.26355/eurrev_202006_21681
- World Health Organization. Chronic obstructive pulmonary disease (COPD). <http://www.emro.who.int/health-topics/chronic-obstructive-pulmonary-disease-copd/index.html>. Accessed January 26, 2021.
- Wang M, Lin EP, Huang LC, Li CY, Shyr Y, Lai CH. Mortality of cardiovascular events in patients with COPD and preceding hospitalization for acute exacerbation. *Chest*. 2020;158(3):973–985. doi:10.1016/j.chest.2020.02.046
- Punekar YS, Riley JH, Lloyd E, Driessen M, Singh SJ. Systematic review of the association between exercise tests and patient-reported outcomes in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2017;Volume 12(12):2487–2506. doi:10.2147/COPD.S100204
- López-Campos JL, Soler-Cataluña JJ, Miravittles M. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2019 report: future challenges. *Arch Bronconeumol*. 2020;56(2):65–67. doi:10.1016/j.arbres.2019.06.001
- Vogelmeier CF, Criner GJ, Martínez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Informe 2017 de la iniciativa global para el diagnóstico, tratamiento y prevención de la enfermedad pulmonar obstructiva crónica: resumen ejecutivo de gold. *Arch Bronconeumol*. 2017;53(3):128–149. doi:10.1016/j.arbres.2017.02.001
- Johnson KM, Safari A, Tan WC, et al. Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD. *Int J Chron Obstruct Pulmon Dis*. 2018;13:3983–3995. doi:10.2147/COPD.S184424
- Herdy AH, Ritt LE, Stein R, et al. Cardiopulmonary exercise test: background, applicability and interpretation. *Arq Bras Cardiol*. 2016;107(5):467–481. doi:10.5935/abc.20160171
- Hsieh MJ, Lan CC, Chen NH, et al. Effects of high-intensity exercise training in a pulmonary rehabilitation programme for patients with chronic obstructive pulmonary disease. *Respirology*. 2007;12(3):381–388. doi:10.1111/j.1440-1843.2007.01077.x
- Song JH, Lee CH, Um SJ, et al. Clinical impacts of the classification by 2017 gold guideline comparing previous ones on outcomes of COPD in real-world cohorts. *Int J Chron Obstruct Pulmon Dis*. 2017; (13):3473–3484.
- Culver BH, Graham BL, Coates AL, et al. Recommendations for a standardized pulmonary function report. An official American thoracic society technical statement. *Am J Respir Crit Care Med*. 2017;196(11):1463–1472. doi:10.1164/rccm.201710-1981ST
- Wasserman K, Hansen JE, Sue DY, et al. *Principles of Exercise Testing and Interpretation*. Fifth ed. Lippincott Williams & Wilkins; 2012:17.
- Wu CW, Hsieh PC, Yang MC, Tzeng IS, Wu YK, Lan CC. Impact of peak oxygen pulse on patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2019;14:2543–2551. doi:10.2147/COPD.S224735
- McConnell AK, Copestake AJ. Maximum static respiratory pressures in healthy elderly men and women: issues of reproducibility and interpretation. *Respiration*. 1999;66(3):251–258. doi:10.1159/000029386
- Wang KY, Chiang CH, Maa SH, Shau WY, Tarn YH. Psychometric assessment of the Chinese language version of the St. George's respiratory questionnaire in Taiwanese patients with bronchial asthma. *J Formos Med Assoc*. 2001;100(7):455–460.
- Cheng ST, Wu YK, Yang MC, et al. Pulmonary rehabilitation improves heart rate variability at peak exercise, exercise capacity and health-related quality of life in chronic obstructive pulmonary disease. *Heart Lung*. 2014;43(3):249–255. doi:10.1016/j.hrtlng.2014.03.002
- Evans JD. *Straightforward Statistics for the Behavioral Sciences*. Pacific Grove, Calif: Brooks/Cole Publishing; 1996.
- Takken T, Mylius CF, Paap D, et al. Reference values for cardiopulmonary exercise testing in healthy subjects - an updated systematic review. *Expert Rev Cardiovasc Ther*. 2019;17(6):413–426. doi:10.1080/14779072.2019.1627874
- Guazzi M, Bandera F, Ozemek C, Systrom D, Arena R. Cardiopulmonary exercise testing? *J Am Coll Cardiol*. 2017;70(13):1618–1636. doi:10.1016/j.jacc.2017.08.012
- O'Donnell DE, Elbehairy AF, Faisal A, Webb KA, Neder JA, Mahler DA. Exertional dyspnoea in COPD: the clinical utility of cardiopulmonary exercise testing. *Eur Respir Rev*. 2016;25(141):333–347. doi:10.1183/16000617.0054-2016
- Bui KL, Nyberg A, Maltais F, Saey D. Functional tests in chronic obstructive pulmonary disease, part 1: clinical relevance and links to the international classification of functioning, disability, and health. *Ann Am Thorac Soc*. 2017;14(5):778–784. doi:10.1513/AnnalsATS.201609-733AS
- Nam HS, Izumchenko E, Dasgupta S, Hoque MO. Mitochondria in chronic obstructive pulmonary disease and lung cancer: where are we now? *Biomark Med*. 2017;11(6):475–489. doi:10.2217/bmm-2016-0373
- Broskey NT, Boss A, Fares EJ, et al. Exercise efficiency relates with mitochondrial content and function in older adults. *Physiol Rep*. 2015;3(6):12418. doi:10.14814/phy2.12418
- Balady GJ, Arena R, Sietsema K, et al. Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American heart association. *Circulation*. 2010;122(2):191–225. doi:10.1161/CIR.0b013e3181e52e69
- Mirdamadi M, Rahimi B, Safavi E, Abtahi H, Peiman S. Correlation of cardiopulmonary exercise testing parameters with quality of life in stable COPD patients. *J Thorac Dis*. 2016;8(8):2138–2145. doi:10.21037/jtd.2016.07.07
- Chuang ML, Huang SF, Su CH. Cardiovascular and respiratory dysfunction in chronic obstructive pulmonary disease complicated by impaired peripheral oxygenation. *Int J Chron Obstruct Pulmon Dis*. 2015;10:329–337. doi:10.2147/COPD.S76209
- Anzueto A, Miravittles M. Pathophysiology of dyspnea in COPD. *Postgrad Med*. 2017;129(3):366–374. doi:10.1080/00325481.2017.1301190

International Journal of Chronic Obstructive Pulmonary Disease**Dovepress****Publish your work in this journal**

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management

protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>